Les commented on the enrollment discrepancy tracks with regard to under enrollment of SOC/placebo by commenting on something he had no certain information about as if he did to keep long term data from being interfered with by anyone snooping around. That worked with sentiment_stocks for a while back then but not with me. It was obvious to me that regulators had interfered with enrollment of SOC patients due to it being a lesser treatment which was indirectly confirmed by Fraunhofer when they said enrollment only occurred to the point statistically necessary in their 2015 annual report. I believe Les could figure out what was going on and offered diversionary commentary to help protect the integrity of the trial data so that patients would not cross over prematurely. Simple as that really. Coming from a lawyer that is pretty benign stuff and certainly not a totally unexpected defense of a tricky situation. Certainly a more nobel cause than what many of the uninvested and those pretending to be invested commenters on this board are doing; ). Best wishes.
Market Data 
Markets 
AI
